Denintuzumab
Based on 1 publication(s) in Google Scholar
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 1630074-14-4
- Molecular Weight:145.96 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Denintuzumab
More
Biological Activity
Human IgG1 kappa
Human
CD19
ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD19 (red) with Denintuzumab (anti-CD19) (HY-P99285). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody. -
Immobilized Hu-CD19-VLP can bind Denintuzumab. The EC50 for this effect is 16 ng/mL.
Chemical Information
-
CAS No. 1630074-14-4
-
Appearance Liquid
-
Molecular Weight 145.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Denintuzumab]
-
Synonyms
hBU 12
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus. [Abstract]2024 Oct;14(10):4560-4576. PMID: 39525579
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)